Trial Profile

Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand PI-2620

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PI 2620 (Primary)
Indications Alzheimer's disease; Frontotemporal dementia
Focus Diagnostic use
Acronyms FPI-2620 FTLD

Most Recent Events

07 Oct 2024 Planned End Date changed from 1 Aug 2026 to 1 Aug 2028.
07 Oct 2024 Planned primary completion date changed from 1 Aug 2026 to 1 Aug 2028.
03 Jul 2023 Number of treatment arms have been increased from 6 to 7 by the addition of Experimental: Amnestic Mild Cognitive Impairment Alzheimer's Disease (MCI/aAD) arm.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com